|
humans |
59 |
|
male |
49 |
|
female |
48 |
|
adult |
46 |
|
medical sciences |
46 |
|
middle aged |
41 |
|
gastroenterology |
32 |
|
adolescent |
29 |
|
hepatocellular carcinoma |
29 |
|
aged |
28 |
|
follow-up studies |
27 |
|
hong kong - epidemiology |
24 |
|
liver transplantation |
24 |
|
hong kong |
22 |
|
child |
21 |
|
hepatitis b |
21 |
|
genotype |
20 |
|
child, preschool |
19 |
|
chronic hepatitis b |
19 |
|
hepatitis b virus |
19 |
|
mutation |
19 |
|
dna, viral - blood |
18 |
|
hepatitis b virus - genetics |
18 |
|
infant |
18 |
|
antiviral agents - therapeutic use |
17 |
|
antiviral therapy |
17 |
|
hcc |
17 |
|
hbv |
16 |
|
predictive value of tests |
16 |
|
treatment outcome |
16 |
|
aged, 80 and over |
15 |
|
alanine transaminase - blood |
15 |
|
hepatitis b, chronic - complications |
15 |
|
prognosis |
15 |
|
time factors |
15 |
|
biomarker |
14 |
|
dna, viral - analysis |
14 |
|
hepatitis b antibodies - blood |
14 |
|
hepatitis b surface antigens - immunology |
14 |
|
lamivudine - therapeutic use |
14 |
|
nafld |
14 |
|
prospective studies |
14 |
|
recurrence |
14 |
|
reverse transcriptase inhibitors - therapeutic use |
14 |
|
gastroenterology medical sciences |
13 |
|
hbsag |
13 |
|
hepatitis b - complications |
13 |
|
liver failure |
13 |
|
retrospective studies |
13 |
|
reverse transcriptase polymerase chain reaction |
13 |
|
risk factors |
13 |
|
surgery |
13 |
|
vaccination |
13 |
|
age factors |
12 |
|
antiviral |
12 |
|
cirrhosis |
12 |
|
drug therapy, combination |
12 |
|
entecavir |
12 |
|
hepatitis b e antigens - blood |
12 |
|
liver stiffness |
12 |
|
prevalence |
12 |
|
survival analysis |
12 |
|
virus replication |
12 |
|
acute flare |
11 |
|
antiviral agents - adverse effects - therapeutic use |
11 |
|
beta catenin |
11 |
|
carcinoma, hepatocellular - etiology - genetics - metabolism |
11 |
|
carcinoma, hepatocellular - virology |
11 |
|
carrier state |
11 |
|
cyclin d1 - biosynthesis - genetics |
11 |
|
cytoskeletal proteins - genetics |
11 |
|
decompensation |
11 |
|
disease progression |
11 |
|
hepatitis c |
11 |
|
liver cirrhosis - complications - diagnosis |
11 |
|
liver neoplasms - virology |
11 |
|
liver transplantation - statistics & numerical data |
11 |
|
longitudinal studies |
11 |
|
meld |
11 |
|
peptidyl-prolyl-isomerase |
11 |
|
peptidylprolyl isomerase - biosynthesis - genetics |
11 |
|
pin1 |
11 |
|
survival rate |
11 |
|
tenofovir |
11 |
|
trans-activators - genetics |
11 |
|
transfection |
11 |
|
β-catenin |
11 |
|
acute disease |
10 |
|
adenine - analogs & derivatives - therapeutic use |
10 |
|
carcinoma, hepatocellular - etiology |
10 |
|
china - ethnology |
10 |
|
chronic disease |
10 |
|
drug resistance, viral - genetics |
10 |
|
gastric cancer |
10 |
|
graft survival |
10 |
|
hepatitis b core antigens - genetics |
10 |
|
hepatitis b surface antigen |
10 |
|
hospitals, university |
10 |
|
incidence |
10 |
|
liver - pathology - virology |
10 |
|
liver cirrhosis - etiology |
10 |
|
liver fibrosis |
10 |
|
liver function tests |
10 |
|
living donors |
10 |
|
m2bpgi |
10 |
|
models, biological |
10 |
|
mortality |
10 |
|
nucleoside analogue |
10 |
|
prevention |
10 |
|
promoter regions, genetic - genetics |
10 |
|
surface antigen |
10 |
|
tissue donors |
10 |
|
adefovir |
9 |
|
alanine transaminase - metabolism |
9 |
|
asian continental ancestry group - statistics & numerical data |
9 |
|
cadaver |
9 |
|
carcinoma, hepatocellular - ethnology - pathology - virology |
9 |
|
chronic viral hepatitis |
9 |
|
fibrosis |
9 |
|
hav |
9 |
|
hbv dna |
9 |
|
hcv |
9 |
|
hepatitis b core-related antigen |
9 |
|
hepatitis b virus - genetics - immunology - isolation & purification |
9 |
|
hepatitis b, chronic - pathology |
9 |
|
hepatitis c virus |
9 |
|
hev |
9 |
|
immigration |
9 |
|
lamivudine |
9 |
|
liver cirrhosis - pathology - virology |
9 |
|
liver diseases - epidemiology |
9 |
|
liver neoplasms - etiology |
9 |
|
liver transplantation - mortality |
9 |
|
nash |
9 |
|
non-viral liver disease |
9 |
|
pre-s deletions |
9 |
|
reproducibility of results |
9 |
|
telbivudine |
9 |
|
transplantation |
9 |
|
tumorigenesis |
9 |
|
asian continental ancestry group |
8 |
|
biological markers - blood |
8 |
|
carcinoma, hepatocellular - surgery - virology |
8 |
|
dose-response relationship, drug |
8 |
|
e-cadherin |
8 |
|
elasticity imaging techniques |
8 |
|
elasticity imaging techniques - methods |
8 |
|
endocrinology |
8 |
|
galectin-1 |
8 |
|
guanine - adverse effects - analogs and derivatives - therapeutic use |
8 |
|
hepatic encephalopathy - surgery |
8 |
|
hepatitis b e antigens - metabolism |
8 |
|
hepatitis b surface antigens - blood |
8 |
|
hepatitis b virus - genetics - immunology |
8 |
|
hepatitis b, chronic - complications - diagnosis |
8 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy - surgery |
8 |
|
hepatitis b, chronic - drug therapy - virology |
8 |
|
hla‐dp |
8 |
|
ifn‐γ pathway |
8 |
|
immune response |
8 |
|
length of stay |
8 |
|
liver - pathology |
8 |
|
liver cirrhosis - surgery - virology |
8 |
|
liver disease |
8 |
|
liver failure - pathology - virology |
8 |
|
mir-22 |
8 |
|
natural history |
8 |
|
nephrotoxicity |
8 |
|
nucleos(t)ide analogue |
8 |
|
nucleoside analogues |
8 |
|
otx008 |
8 |
|
outcomes |
8 |
|
phosphonic acids |
8 |
|
polymorphism, genetic |
8 |
|
postoperative complications |
8 |
|
protein precursors - genetics |
8 |
|
reoperation |
8 |
|
resistance |
8 |
|
severity of illness index |
8 |
|
sex factors |
8 |
|
therapeutics |
8 |
|
viral hepatitis |
8 |
|
accuracy |
7 |
|
adoptive transfer |
7 |
|
alanine aminotransferase blood level |
7 |
|
alpha-fetoproteins - analysis |
7 |
|
asia |
7 |
|
cadaveric transplantation |
7 |
|
cap |
7 |
|
case-control studies |
7 |
|
controlled attenuation parameter |
7 |
|
diagnostic test accuracy study |
7 |
|
disease severity |
7 |
|
drug response |
7 |
|
elastography |
7 |
|
etv |
7 |
|
functional cure |
7 |
|
hepacivirus - genetics |
7 |
|
hepatitis b - drug therapy - prevention & control - surgery |
7 |
|
hepatitis b antibodies |
7 |
|
hepatitis b surface antigens - blood - immunology |
7 |
|
hepatitis b virus - classification - genetics |
7 |
|
hepatitis b virus - drug effects - genetics |
7 |
|
hepatitis b virus - physiology |
7 |
|
hepatitis b virus infection |
7 |
|
hepatitis b, chronic - blood - drug therapy - virology |
7 |
|
hepatitis b, chronic - enzymology - pathology |
7 |
|
immunosuppressive agents - therapeutic use |
7 |
|
interferon-alpha - therapeutic use |
7 |
|
intraoperative complications - epidemiology |
7 |
|
itraq |
7 |
|
lamivudine - adverse effects - therapeutic use |
7 |
|
liver - chemistry - pathology |
7 |
|
liver cirrhosis - enzymology - pathology |
7 |
|
liver diseases - epidemiology - surgery |
7 |
|
metabolic |
7 |
|
mutation - genetics |
7 |
|
obesity |
7 |
|
olt |
7 |
|
placebos |
7 |
|
polymerase chain reaction - methods |
7 |
|
postoperative complications - epidemiology |
7 |
|
postoperative complications - prevention & control |
7 |
|
preoperative care |
7 |
|
promoter regions, genetic |
7 |
|
recombinant proteins |
7 |
|
response to therapy |
7 |
|
sepsis - prevention & control |
7 |
|
seroepidemiologic studies |
7 |
|
transient elastography |
7 |
|
viral core proteins - genetics |
7 |
|
viral load |
7 |
|
waiting lists |
7 |
|
young adult |
7 |
|
acute kidney injury - surgery |
6 |
|
adrenal cortex hormones - administration & dosage |
6 |
|
age |
6 |
|
alanine aminotransferase |
6 |
|
alkaline phosphatase - blood |
6 |
|
anti-hbc |
6 |
|
anti-hbs |
6 |
|
antibodies, monoclonal - administration & dosage - therapeutic use |
6 |
|
antibody to hepatitis b surface antigen |
6 |
|
antigens, viral - blood |
6 |
|
antineoplastic agents, hormonal - administration & dosage |
6 |
|
aspartate aminotransferase |
6 |
|
biopsy |
6 |
|
blood donors - statistics and numerical data |
6 |
|
blood loss, surgical |
6 |
|
body weight |
6 |
|
carcinoma, hepatocellular - blood - metabolism |
6 |
|
carcinoma, hepatocellular - diagnosis - epidemiology |
6 |
|
carcinoma, hepatocellular - drug therapy - mortality |
6 |
|
carcinoma, hepatocellular - epidemiology - genetics - virology |
6 |
|
carcinoma, hepatocellular - etiology - pathology - surgery - virology |
6 |
|
carrier state - epidemiology - pathology |
6 |
|
cccdna |
6 |
|
cell line, tumor |
6 |
|
cholangiopancreatography, endoscopic retrograde |
6 |
|
chromosome 8p |
6 |
|
chronic kidney disease |
6 |
|
circular dna |
6 |
|
cohort studies |
6 |
|
covalently closed circular dna |
6 |
|
cyclosporine - therapeutic use |
6 |
|
cytomegalovirus - immunology |
6 |
|
data mining |
6 |
|
diabetes mellitus - epidemiology - prevention & control |
6 |
|
dkk1 |
6 |
|
dna methylation |
6 |
|
drug resistance, viral |
6 |
|
enhancer elements (genetics) - genetics |
6 |
|
epidemiology |
6 |
|
fatty liver |
6 |
|
fibroscan |
6 |
|
full-length genome sequencing |
6 |
|
genetic association |
6 |
|
genotype 1 |
6 |
|
genotype 6 |
6 |
|
graft rejection - epidemiology - prevention & control |
6 |
|
guanine - analogs and derivatives - therapeutic use |
6 |
|
hbeag |
6 |
|
hbeag seroconversion |
6 |
|
hepacivirus - classification - genetics - pathogenicity |
6 |
|
hepaticolenticular degeneration |
6 |
|
hepatitis b - prevention & control - surgery |
6 |
|
hepatitis b core‐related antigen |
6 |
|
hepatitis b serum markers |
6 |
|
hepatitis b surface antigens - analysis - blood |
6 |
|
hepatitis b virus - drug effects |
6 |
|
hepatitis b virus - isolation and purification |
6 |
|
hepatitis b(e) antigen |
6 |
|
hepatitis b, chronic - blood - complications - genetics |
6 |
|
hepatitis b, chronic - blood - complications - immunology - pathology - virology |
6 |
|
hepatitis b, chronic - complications - drug therapy |
6 |
|
hepatitis b, chronic - complications - virology |
6 |
|
hepatitis b, chronic - drug therapy - enzymology - immunology |
6 |
|
hepatitis b, chronic - epidemiology - pathology |
6 |
|
hepatitis b, chronic - ethnology - immunology - pathology |
6 |
|
hepatitis b, chronic - mortality - surgery |
6 |
|
hepatitis c, chronic - complications - metabolism - virology |
6 |
|
hepatitis c, chronic - drug therapy - virology |
6 |
|
host-pathogen interactions |
6 |
|
hs-hbsag |
6 |
|
immunoglobulins - therapeutic use |
6 |
|
immunosuppressive agents - administration & dosage - therapeutic use |
6 |
|
inflammation |
6 |
|
informed consent |
6 |
|
injections, intravenous |
6 |
|
intercellular signaling peptides and proteins - blood - metabolism |
6 |
|
interleukin‐27 |
6 |
|
intrahepatic hbv dna |
6 |
|
jnk |
6 |
|
kinetics |
6 |
|
lamivudine - pharmacology - therapeutic use |
6 |
|
liver |
6 |
|
liver - pathology - ultrasonography |
6 |
|
liver biopsy |
6 |
|
liver carcinogenesis |
6 |
|
liver cirrhosis - ethnology - pathology - virology |
6 |
|
liver diseases - surgery |
6 |
|
liver neoplasms - blood - metabolism |
6 |
|
liver neoplasms - diagnosis - epidemiology |
6 |
|
liver neoplasms - drug therapy - mortality |
6 |
|
liver neoplasms - epidemiology - genetics - virology |
6 |
|
liver neoplasms - ethnology - pathology - virology |
6 |
|
liver neoplasms - etiology - pathology - surgery - virology |
6 |
|
liver transplantation - adverse effects |
6 |
|
liver transplantation - adverse effects - immunology |
6 |
|
liver transplantation - adverse effects - methods |
6 |
|
liver transplantation - immunology |
6 |
|
liver transplantation - methods |
6 |
|
longitudinal |
6 |
|
mac-2 binding protein glycosylation isomer |
6 |
|
mass screening - methods |
6 |
|
metabolic syndrome |
6 |
|
mycophenolic acid - administration & dosage - analogs & derivatives |
6 |
|
na therapy |
6 |
|
nucleotide analogue |
6 |
|
octreotide - administration & dosage |
6 |
|
organ size |
6 |
|
platelet ratio index |
6 |
|
postoperative care |
6 |
|
prediction |
6 |
|
primary biliary cholangitis |
6 |
|
promoter regions (genetics) - genetics |
6 |
|
proportional hazards models |
6 |
|
quasispecies |
6 |
|
receptors, interleukin-2 - immunology |
6 |
|
recombinant fusion proteins |
6 |
|
recurrence - prevention & control |
6 |
|
ribavirin |
6 |
|
risk factor |
6 |
|
rna-directed dna polymerase - genetics |
6 |
|
safety |
6 |
|
spontaneous hbeag seroconversion |
6 |
|
stc1 |
6 |
|
tacrolimus - administration & dosage |
6 |
|
tacrolimus - therapeutic use |
6 |
|
tenofovir hbsag surface antigen nucleoside analogue nucleotide analogue tdf |
6 |
|
tissue and organ procurement - organization & administration |
6 |
|
tumor markers, biological - blood |
6 |
|
tumor markers, biological - blood - metabolism |
6 |
|
ursodeoxycholic acid |
6 |
|
viral suppression |
6 |
|
virus dna |
6 |
|
wfa + -m2bp |
6 |
|
wnt |
6 |
|
adenocarcinoma - blood - diagnosis |
5 |
|
adrenal cortex hormones - therapeutic use |
5 |
|
alanine transaminase - analysis |
5 |
|
anaemia |
5 |
|
anti-inflammatory agents, non-steroidal - adverse effects |
5 |
|
anti-ulcer agents - therapeutic use |
5 |
|
antineoplastic agents - administration & dosage |
5 |
|
antiviral agents - administration and dosage - therapeutic use |
5 |
|
apoptosis |
5 |
|
aspartate aminotransferases - blood |
5 |
|
azathioprine - therapeutic use |
5 |
|
besifovir |
5 |
|
biliary tract diseases - chemically induced - diagnosis |
5 |
|
bilirubin - blood |
5 |
|
blood transfusion - adverse effects |
5 |
|
cadherins - blood |
5 |
|
carcinoma, hepatocellular - complications - surgery |
5 |
|
carcinoma, hepatocellular - diagnosis - pathology |
5 |
|
carcinoma, hepatocellular - therapy |
5 |
|
ceruloplasmin - metabolism |
5 |
|
chemoembolization, therapeutic - methods |
5 |
|
china |
5 |
|
cholestasis, intrahepatic - drug therapy - etiology - surgery |
5 |
|
codon |
5 |
|
copper/urine |
5 |
|
core antigen |
5 |
|
core protein |
5 |
|
core protein allosteric modulator |
5 |
|
cure |
5 |
|
deep sequencing |
5 |
|
dna mutational analysis - methods |
5 |
|
dna, circular - analysis - isolation & purification |
5 |
|
dna, viral - analysis - isolation & purification |
5 |
|
dna, viral - genetics |
5 |
|
dna, viral - metabolism |
5 |
|
dna-directed dna polymerase - genetics |
5 |
|
drugs, chinese herbal - adverse effects |
5 |
|
efficacy |
5 |
|
emergency medical services |
5 |
|
enzyme inhibitors - therapeutic use |
5 |
|
flare |
5 |
|
freezing |
5 |
|
gamma-glutamyltransferase - blood |
5 |
|
gene deletion |
5 |
|
gene expression regulation, viral |
5 |
|
genetic predisposition to disease |
5 |
|
globulins - analysis |
5 |
|
graft rejection - drug therapy |
5 |
|
guanine - administration and dosage - analogs and derivatives - therapeutic use |
5 |
|
h(+)-k(+)-exchanging atpase - antagonists & inhibitors |
5 |
|
hbcrag |
5 |
|
hbsag seroclearance |
5 |
|
hbx protein |
5 |
|
helicobacter pylori |
5 |
|
hepatectomy - methods |
5 |
|
hepatitic decompensation |
5 |
|
hepatitis b - complications - drug therapy - surgery |
5 |
|
hepatitis b - drug therapy - genetics - physiopathology - virology |
5 |
|
hepatitis b antibodies - analysis |
5 |
|
hepatitis b core antigens - genetics - immunology |
5 |
|
hepatitis b e antigen |
5 |
|
hepatitis b e antigen seroconversion |
5 |
|
hepatitis b e antigens - biosynthesis - genetics - immunology |
5 |
|
hepatitis b surface antigens - blood - chemistry |
5 |
|
hepatitis b surface antigens - genetics |
5 |
|
hepatitis b surface antigens - metabolism |
5 |
|
hepatitis b virus - chemistry - classification - genetics |
5 |
|
hepatitis b virus - drug effects - enzymology - genetics |
5 |
|
hepatitis b virus - genetics - immunology - isolation and purification |
5 |
|
hepatitis b virus - genetics - isolation and purification |
5 |
|
hepatitis b virus dna rebound |
5 |
|
hepatitis b virus replication |
5 |
|
hepatitis b, chronic - blood - drug therapy |
5 |
|
hepatitis b, chronic - blood - pathology - virology |
5 |
|
hepatitis b, chronic - complications - genetics - virology |
5 |
|
hepatitis b, chronic - complications - mortality - pathology |
5 |
|
hepatitis b, chronic - drug therapy |
5 |
|
hepatitis b, chronic - epidemiology - physiopathology - virology |
5 |
|
hepatitis b, chronic - genetics - immunology - virology |
5 |
|
hepatitis b, chronic - immunology - surgery |
5 |
|
hepatolenticular degeneration - complications - diagnosis - drug therapy - genetics - metabolism |
5 |
|
hospital mortality |
5 |
|
hypertension - epidemiology |
5 |
|
inhalant abuse - complications |
5 |
|
interferon-gamma - biosynthesis - immunology |
5 |
|
interleukin-10 - immunology |
5 |
|
interleukin-2 - immunology |
5 |
|
interleukin-4 - immunology |
5 |
|
interleukin-5 - immunology |
5 |
|
intrahepatic hepatitis b virus dna |
5 |
|
ketamine - administration and dosage - adverse effects |
5 |
|
lamivudine - administration & dosage - therapeutic use |
5 |
|
linearized hbsag |
5 |
|
liver - metabolism |
5 |
|
liver - radiography |
5 |
|
liver - virology |
5 |
|
liver biochemistry |
5 |
|
liver cirrhosis - diagnosis |
5 |
|
liver cirrhosis - drug therapy - etiology - surgery |
5 |
|
liver diseases - diagnosis - etiology |
5 |
|
liver diseases - etiology |
5 |
|
liver failure - etiology - surgery |
5 |
|
liver failure - surgery |
5 |
|
liver histology |
5 |
|
liver neoplasms |
5 |
|
liver neoplasms - complications - surgery |
5 |
|
liver neoplasms - therapy |
5 |
|
liver transplantation - immunology - methods - physiology |
5 |
|
liver transplantation - immunology - mortality - physiology |
5 |
|
liver transplantation - methods - mortality - statistics & numerical data |
5 |
|
liver transplantation - mortality - physiology - statistics & numerical data |
5 |
|
lung - radiography |
5 |
|
lymphocyte activation |
5 |
|
lymphocytes - immunology |
5 |
|
medical sciences - oncology |
5 |
|
medical sciences - urology and nephrology |
5 |
|
medicine, chinese traditional - adverse effects |
5 |
|
multivariate analysis |
5 |
|
myopathy |
5 |
|
nuclear family |
5 |
|
nucleocapsid |
5 |
|
nucleosides - pharmacology - therapeutic use |
5 |
|
occult hepatitis b infection |
5 |
|
patient selection |
5 |
|
peptic ulcer - chemically induced - microbiology - prevention & control |
5 |
|
polyethylene glycols - therapeutic use |
5 |
|
precore mutation |
5 |
|
promoter regions (genetics) |
5 |
|
protein stability |
5 |
|
pyrimidinones - pharmacology - therapeutic use |
5 |
|
quantitative |
5 |
|
reverse transcriptase inhibitors - administration & dosage - therapeutic use |
5 |
|
ribavirin - therapeutic use |
5 |
|
rna, messenger - analysis - isolation & purification |
5 |
|
rna, viral - analysis - isolation & purification |
5 |
|
roc curve |
5 |
|
sensitivity and specificity |
5 |
|
seroclearance |
5 |
|
serologic tests |
5 |
|
serology |
5 |
|
severe acute respiratory syndrome - blood - complications - radiography |
5 |
|
severe hepatitis b exacerbation |
5 |
|
single polynucleotide polymorphisms |
5 |
|
specimen handling - methods |
5 |
|
statistics, nonparametric |
5 |
|
stomach neoplasms - blood - diagnosis |
5 |
|
stopping |
5 |
|
sustained virologic response |
5 |
|
t helper response |
5 |
|
th1 cells - immunology |
5 |
|
th2 cells - immunology |
5 |
|
tissue donors - supply & distribution |
5 |
|
tomography, x-ray computed |
5 |
|
transcription |
5 |
|
translation |
5 |
|
treatment guidelines |
5 |
|
tumor |
5 |
|
tumour marker |
5 |
|
urologic diseases - chemically induced |
5 |
|
virology |
5 |
|
week 12 |
5 |
|
week 24 |
5 |
|
wilson disease |
5 |
|
ymdd mutation |
5 |
|
actins - genetics |
4 |
|
actuarial analysis |
4 |
|
adverse effects |
4 |
|
age distribution |
4 |
|
age of onset |
4 |
|
allergology and immunology |
4 |
|
amino acid motifs - drug effects - genetics |
4 |
|
analysis of variance |
4 |
|
anti-hiv agents - therapeutic use |
4 |
|
antiviral agents - pharmacology - therapeutic use |
4 |
|
antiviral treatment |
4 |
|
as-apex |
4 |
|
asian continental ancestry group - ethnology |
4 |
|
asian continental ancestry group - genetics |
4 |
|
aspartic acid - drug effects - genetics |
4 |
|
atp7b |
4 |
|
base sequence |
4 |
|
biopsy - methods |
4 |
|
blood - virology |
4 |
|
blood donors |
4 |
|
blood transfusion |
4 |
|
breast feeding |
4 |
|
cancer |
4 |
|
capsid inhibitor |
4 |
|
carbocyanines |
4 |
|
carcinoma, hepatocellular - blood - complications - genetics |
4 |
|
carcinoma, hepatocellular - diagnosis - virology |
4 |
|
carcinoma, hepatocellular - mortality - pathology - therapy |
4 |
|
carcinoma, hepatocellular - mortality - therapy |
4 |
|
carnitine |
4 |
|
carrier proteins - blood - genetics |
4 |
|
chemoembolization, therapeutic - adverse effects - methods |
4 |
|
chronic liver disease |
4 |
|
cisplatin - administration & dosage |
4 |
|
complement c4 - metabolism |
4 |
|
complications of hbv reactivation |
4 |
|
contrast media - administration & dosage |
4 |
|
core promoter mutation |
4 |
|
core-promoter mutation |
4 |
|
cross-sectional studies |
4 |
|
deoxycytosine nucleotides |
4 |
|
dialysis |
4 |
|
direct acting antiviral |
4 |
|
dna methylation - immunology |
4 |
|
dna mutational analysis |
4 |
|
dna polymerase inhibitor |
4 |
|
dna, circular - analysis |
4 |
|
dna, circular - blood - drug effects |
4 |
|
dna, viral - blood - drug effects |
4 |
|
dna, viral - blood - isolation & purification |
4 |
|
dna, viral - genetics - isolation and purification |
4 |
|
dose-response relationship, immunologic |
4 |
|
drug interaction |
4 |
|
drug resistance, multiple, viral - genetics |
4 |
|
drug-resistant mutations |
4 |
|
elasticity |
4 |
|
entry inhibitor |
4 |
|
enzyme-linked immunosorbent assay |
4 |
|
enzyme-linked immunosorbent assay - methods |
4 |
|
estrogen |
4 |
|
extrahepatic manifestation of hbv |
4 |
|
fanconi syndrome |
4 |
|
gastritis/genetics - immunology/prevention & control |
4 |
|
gender difference |
4 |
|
gene frequency |
4 |
|
gene products, pol - genetics |
4 |
|
genetic heterogeneity |
4 |
|
guanine - analogs & derivatives - therapeutic use |
4 |
|
haplotype |
4 |
|
haplotypes |
4 |
|
hbv array |
4 |
|
hbv infection |
4 |
|
hbv transcription |
4 |
|
health status indicators |
4 |
|
health surveys |
4 |
|
health-related quality of life |
4 |
|
helicobacter infections/genetics - immunology/microbiology |
4 |
|
hepatic artery |
4 |
|
hepatitis b - drug therapy - genetics |
4 |
|
hepatitis b - drug therapy - genetics - virology |
4 |
|
hepatitis b - drug therapy - virology |
4 |
|
hepatitis b - immunology - prevention & control |
4 |
|
hepatitis b - pathology |
4 |
|
hepatitis b - prevention & control - surgery - therapy |
4 |
|
hepatitis b - transmission |
4 |
|
hepatitis b - virology |
4 |
|
hepatitis b antibodies - blood - immunology |
4 |
|
hepatitis b core antigens - blood |
4 |
|
hepatitis b core antigens - immunology |
4 |
|
hepatitis b core antigens - metabolism |
4 |
|
hepatitis b core protein |
4 |
|
hepatitis b e antigen (hbeag) |
4 |
|
hepatitis b genotype |
4 |
|
hepatitis b surface antigens |
4 |
|
hepatitis b surface antigens - analysis - immunology |
4 |
|
hepatitis b surface antigens - blood - metabolism |
4 |
|
hepatitis b vaccines - administration & dosage - immunology |
4 |
|
hepatitis b virus (hbv) dna |
4 |
|
hepatitis b virus - chemistry |
4 |
|
hepatitis b virus - classification - genetics - isolation & purification - pathogenicity |
4 |
|
hepatitis b virus - classification - genetics - isolation and purification |
4 |
|
hepatitis b virus - genetics - isolation & purification |
4 |
|
hepatitis b, chronic - blood - drug therapy - genetics |
4 |
|
hepatitis b, chronic - blood - drug therapy - immunology |
4 |
|
hepatitis b, chronic - classification - diagnosis |
4 |
|
hepatitis b, chronic - complications - drug therapy - ethnology |
4 |
|
hepatitis b, chronic - complications - ethnology - therapy |
4 |
|
hepatitis b, chronic - diagnosis |
4 |
|
hepatitis b, chronic - drug therapy - ethnology - pathology |
4 |
|
hepatitis b, chronic - epidemiology |
4 |
|
hepatitis b, chronic - etiology |
4 |
|
hepatitis b, chronic - genetics - metabolism - pathology |
4 |
|
hepatitis b, chronic - metabolism |
4 |
|
hepatitis b, chronic - metabolism - physiopathology |
4 |
|
hepatitis b, chronic - pathology - physiopathology |
4 |
|
hepatitis b, chronic - physiopathology |
4 |
|
hepatitis b, chronic - physiopathology - virology |
4 |
|
hepatitis b, chronic - psychology |
4 |
|
hepatitis c, chronic - epidemiology |
4 |
|
hepatolenticular degeneration - genetics |
4 |
|
high mortality of acute pancreatitis |
4 |
|
histology |
4 |
|
histone acetylation |
4 |
|
hong kong chinese |
4 |
|
hsct |
4 |
|
hypertension, portal - complications - surgery |
4 |
|
immunization |
4 |
|
immunization schedule |
4 |
|
immunization, secondary |
4 |
|
immunogenicity |
4 |
|
immunohistochemistry |
4 |
|
immunologic memory |
4 |
|
immunomodulator |
4 |
|
injections, intra-arterial - methods |
4 |
|
interleukin-1 receptor type 1 knockout mice |
4 |
|
interleukin-1b |
4 |
|
interleukin-1beta/genetics - immunology/metabolism |
4 |
|
interleukin-1β |
4 |
|
iodized oil - administration & dosage |
4 |
|
isoleucine - genetics |
4 |
|
kidney transplantation |
4 |
|
killer cells, lymphokine-activated - transplantation |
4 |
|
lactic acidosis |
4 |
|
lamivudine - administration & dosage |
4 |
|
lb80380 |
4 |
|
limit of detection |
4 |
|
linkage disequilibrium |
4 |
|
liver - anatomy and histology |
4 |
|
liver cirrhosis - complications |
4 |
|
liver cirrhosis - diagnosis - epidemiology - virology |
4 |
|
liver cirrhosis - genetics |
4 |
|
liver cirrhosis - pathology |
4 |
|
liver cirrhosis - pathology - physiopathology |
4 |
|
liver cirrhosis - physiopathology - virology |
4 |
|
liver cirrhosis - virology |
4 |
|
liver neoplasms - blood - complications - genetics |
4 |
|
liver neoplasms - diagnosis - virology |
4 |
|
liver neoplasms - mortality - pathology - therapy |
4 |
|
liver neoplasms - mortality - therapy |
4 |
|
luminescent measurements - methods |
4 |
|
mannose-binding lectin - blood - genetics - metabolism |
4 |
|
methionine - drug effects - genetics |
4 |
|
microrna |
4 |
|
muscle toxicity |
4 |
|
mutation, missense - genetics |
4 |
|
necroinflammation |
4 |
|
necrosis - pathology |
4 |
|
neoplasm staging |
4 |
|
nitric oxide |
4 |
|
noninvasive |
4 |
|
novel mutation |
4 |
|
novel therapy |
4 |
|
nucleos(t)ide analogs |
4 |
|
nucleoside analog |
4 |
|
nucleoside/ nucleotide analogue |
4 |
|
nucleotide analog |
4 |
|
oligonucleotide array sequence analysis - methods |
4 |
|
oral therapy |
4 |
|
organ size - physiology |
4 |
|
osteomalacia |
4 |
|
p.r778l founder mutation |
4 |
|
pancreatitis - diagnosis - etiology |
4 |
|
peripheral neuropathy |
4 |
|
peritonitis - blood - complications - genetics |
4 |
|
pharmacokinetics |
4 |
|
phosphonic acids - therapeutic use |
4 |
|
polymerase inhibitor |
4 |
|
preventive medicine - methods |
4 |
|
protease inhibitor |
4 |
|
protein-losing enteropathies - etiology - surgery |
4 |
|
psychometrics |
4 |
|
quality of life |
4 |
|
questionnaires |
4 |
|
questionnaires - standards |
4 |
|
real-life |
4 |
|
receptors, interleukin-1 type i/genetics - immunology/metabolism |
4 |
|
recombinant proteins - adverse effects |
4 |
|
renal replacement therapy |
4 |
|
renal toxicity |
4 |
|
renal transplantation |
4 |
|
reverse transcriptase inhibitors - administration & dosage |
4 |
|
rituximab |
4 |
|
rnai |
4 |
|
sex distribution |
4 |
|
southern chinese |
4 |
|
statistics as topic |
4 |
|
survival |
4 |
|
teratogenecity |
4 |
|
therapeutic vaccine |
4 |
|
tlr7 agonist |
4 |
|
treatment |
4 |
|
tyrosine - drug effects - genetics |
4 |
|
vaccines, dna - administration & dosage - immunology |
4 |
|
validity |
4 |
|
valine - genetics |
4 |
|
viral envelope proteins - genetics |
4 |
|
viremia - complications |
4 |
|
acute-on-chronic liver failure |
3 |
|
adrenal gland neoplasms - complications |
3 |
|
adrenal insufficiency - drug therapy - etiology |
3 |
|
adrenocortical insufficiency. |
3 |
|
alcoholic liver disease |
3 |
|
alpha-fetoproteins - metabolism |
3 |
|
ambulatory care facilities - utilization |
3 |
|
ambulatory surgical procedures |
3 |
|
anemia, hemolytic - diagnosis - etiology |
3 |
|
anemia, refractory - diagnosis - etiology - therapy |
3 |
|
antibodies, viral - analysis |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
antiviral agents - administration & dosage - adverse effects - pharmacokinetics - therapeutic use |
3 |
|
antiviral agents - administration and dosage |
3 |
|
appendicitis - complications - diagnosis |
3 |
|
arc-520 |
3 |
|
automation - instrumentation - methods |
3 |
|
bacteriophage m13 - genetics |
3 |
|
bile duct neoplasms - complications - mortality - therapy |
3 |
|
bile ducts, intrahepatic - pathology - radiography - ultrasonography |
3 |
|
biliary tract diseases - therapy |
3 |
|
biological markers |
3 |
|
bone marrow - immunology |
3 |
|
bone marrow transplantation |
3 |
|
carcinogenesis |
3 |
|
carcinoma |
3 |
|
carcinoma, hepatocellular |
3 |
|
carcinoma, hepatocellular - drug therapy - secondary - surgery |
3 |
|
carcinoma, hepatocellular - epidemiology - virology |
3 |
|
carrier state - drug therapy |
3 |
|
chemoembolization, therapeutic |
3 |
|
cholangiocarcinoma |
3 |
|
cholangiocarcinoma - complications - mortality - therapy |
3 |
|
cholangiopancreatography, endoscopic retrograde - adverse effects - methods |
3 |
|
cholangitis - etiology |
3 |
|
cholangitis - surgery - therapy |
3 |
|
cholecystectomy - methods |
3 |
|
choledocholithiasis - complications - surgery |
3 |
|
cholestasis - drug therapy |
3 |
|
chronic hepatitis b therapy |
3 |
|
chronic viral infection |
3 |
|
clinical criteria for same-day discharge |
3 |
|
clinical trials as topic |
3 |
|
comorbidity |
3 |
|
complications |
3 |
|
core promoter mutations |
3 |
|
core-promoter |
3 |
|
covid-19 |
3 |
|
creatine kinase |
3 |
|
creatine kinase - blood |
3 |
|
decompression, surgical |
3 |
|
deranged liver function |
3 |
|
direct-acting antiviral |
3 |
|
dna primers |
3 |
|
dna, viral - genetics - isolation & purification |
3 |
|
double-blind method |
3 |
|
drainage |
3 |
|
drug monitoring |
3 |
|
drug resistance |
3 |
|
drug-induced liver injury |
3 |
|
dyspepsia |
3 |
|
dyspepsia - diagnosis |
3 |
|
emergencies |
3 |
|
end stage liver disease - etiology - therapy |
3 |
|
endoscopic retrograde cholangiopancreatography |
3 |
|
endoscopy, gastrointestinal |
3 |
|
endoscopy, gastrointestinal - utilization |
3 |
|
enoxaparin - adverse effects |
3 |
|
erythrocytes, abnormal - ultrastructure |
3 |
|
etiology |
3 |
|
eurohep reference plasma |
3 |
|
europe - epidemiology |
3 |
|
family characteristics |
3 |
|
family practice - organization & administration |
3 |
|
flaviviridae infections - epidemiology |
3 |
|
fluorescent antibody technique |
3 |
|
gallstones - therapy |
3 |
|
gastrointestinal neoplasms - diagnosis |
3 |
|
gb virus c |
3 |
|
glomerulonephritis, iga - etiology - pathology |
3 |
|
guanine - adverse effects - analogs & derivatives - pharmacology - therapeutic use |
3 |
|
hbeag seroreversion |
3 |
|
hbv dna assays |
3 |
|
hbv-dna |
3 |
|
health services accessibility - organization & administration |
3 |
|
hemodialysis |
3 |
|
hepacivirus - classification - genetics |
3 |
|
hepacivirus - drug effects - genetics |
3 |
|
hepacivirus - genetics - isolation and purification |
3 |
|
hepacivirus - immunology |
3 |
|
hepacivirus - isolation & purification |
3 |
|
hepacivirus - pathogenicity |
3 |
|
hepatectomy |
3 |
|
hepatic |
3 |
|
hepatitis - diagnosis - etiology |
3 |
|
hepatitis b - blood - diagnosis |
3 |
|
hepatitis b - complications - drug therapy |
3 |
|
hepatitis b - complications - virology |
3 |
|
hepatitis b - prevention & control |
3 |
|
hepatitis b e antigens - analysis |
3 |
|
hepatitis b e antigens - genetics |
3 |
|
hepatitis b treatment |
3 |
|
hepatitis b vaccines |
3 |
|
hepatitis b vaccines - administration & dosage |
3 |
|
hepatitis b virus - drug effects - genetics - isolation & purification |
3 |
|
hepatitis b virus - drug effects - isolation & purification |
3 |
|
hepatitis b virus - genetics - isolation & purification - pathogenicity |
3 |
|
hepatitis b virus - genetics - isolation & purification - physiology |
3 |
|
hepatitis b virus - pathogenicity |
3 |
|
hepatitis b virus dna |
3 |
|
hepatitis b, chronic - blood - complications |
3 |
|
hepatitis b, chronic - blood - diagnosis |
3 |
|
hepatitis b, chronic - complications - epidemiology |
3 |
|
hepatitis b, chronic - complications - epidemiology - genetics |
3 |
|
hepatitis b, chronic - diagnosis - drug therapy |
3 |
|
hepatitis b, chronic - diagnosis - drug therapy - immunology - virology |
3 |
|
hepatitis b, chronic - epidemiology - immunology - virology |
3 |
|
hepatitis b, chronic - virology |
3 |
|
hepatitis c - complications - virology |
3 |
|
hepatitis c - epidemiology - virology |
3 |
|
hepatitis c, chronic - drug therapy - genetics - virology |
3 |
|
hepatitis c, chronic - epidemiology - mortality |
3 |
|
hepatitis e - immunology |
3 |
|
hepatitis e virus - immunology |
3 |
|
hepato-cellular carcinoma |
3 |
|
hepatocellular |
3 |
|
hiv infections - epidemiology - virology |
3 |
|
hiv-1 - classification - genetics |
3 |
|
hydrocortisone - therapeutic use |
3 |
|
hypoceruloplasminemia |
3 |
|
immunocompromised host |
3 |
|
immunoenzyme techniques |
3 |
|
immunologic factors - therapeutic use |
3 |
|
immunosuppression |
3 |
|
immunotherapy, adoptive - adverse effects |
3 |
|
infection control |
3 |
|
interferon |
3 |
|
interferon alfa-2b - pharmacology - therapeutic use |
3 |
|
interferon-alfa |
3 |
|
interferon-alpha - administration & dosage - adverse effects |
3 |
|
interferon-α |
3 |
|
interferons |
3 |
|
interleukin-2 - adverse effects |
3 |
|
interleukins - genetics - therapeutic use |
3 |
|
ischemia - chemically induced |
3 |
|
isoenzymes - blood |
3 |
|
jnj-3989 |
3 |
|
kidney - pathology |
3 |
|
kidney failure, chronic - mortality - therapy |
3 |
|
kidney transplantation - adverse effects |
3 |
|
kidney transplantation - mortality |
3 |
|
lamivudine - administration and dosage |
3 |
|
lithotripsy - methods |
3 |
|
liver - drug effects - pathology - physiopathology |
3 |
|
liver cirrhosis |
3 |
|
liver cirrhosis - blood - complications - virology |
3 |
|
liver cirrhosis - complications - mortality - therapy |
3 |
|
liver cirrhosis, alcoholic - complications |
3 |
|
liver cirrhosis, biliary - epidemiology |
3 |
|
liver diseases - epidemiology - etiology |
3 |
|
liver diseases - etiology - pathology |
3 |
|
liver diseases, alcoholic - epidemiology |
3 |
|
liver failure, acute - etiology - therapy |
3 |
|
liver neoplasms - drug therapy - pathology - surgery |
3 |
|
logistic models |
3 |
|
lung metastasis |
3 |
|
lung neoplasms - drug therapy - secondary - surgery |
3 |
|
lymphocyte |
3 |
|
lymphoma, non-hodgkin - complications |
3 |
|
median survival |
3 |
|
meta-analysis |
3 |
|
model of end-stage liver disease |
3 |
|
monitor |
3 |
|
multicenter studies as topic - statistics & numerical data |
3 |
|
muscular diseases - blood - chemically induced |
3 |
|
mutants |
3 |
|
myrcludex b |
3 |
|
nadroparin - adverse effects |
3 |
|
natural killer cell |
3 |
|
neurotoxicity |
3 |
|
non‐hodgkin's lymphoma |
3 |
|
nucleosides - administration & dosage - adverse effects - pharmacokinetics - therapeutic use |
3 |
|
ocular complication |
3 |
|
oligodeoxyribonucleotides |
3 |
|
open-access |
3 |
|
outcome and process assessment (health care) |
3 |
|
outpatient |
3 |
|
pancreatitis - etiology - prevention & control |
3 |
|
patient readmission |
3 |
|
pedigree |
3 |
|
peripheral nervous system diseases - chemically induced |
3 |
|
peritoneal dialysis |
3 |
|
phosphonic acids - adverse effects - pharmacology - therapeutic use |
3 |
|
pilot projects |
3 |
|
plasmids |
3 |
|
platelet count |
3 |
|
pneumonectomy |
3 |
|
polymerase chain reaction |
3 |
|
polymorphism, single nucleotide |
3 |
|
portal vein thrombosis |
3 |
|
post-therapeutic complication |
3 |
|
postoperative complications - virology |
3 |
|
postoperative period |
3 |
|
practice guidelines as topic |
3 |
|
pre-core |
3 |
|
precore mutations |
3 |
|
pregnancy |
3 |
|
pregnancy complications, infectious - drug therapy |
3 |
|
primary biliary cirrhosis |
3 |
|
prothrombin time |
3 |
|
pulmonary embolism - drug therapy |
3 |
|
pyrimidinones - administration & dosage - adverse effects - pharmacokinetics - therapeutic use |
3 |
|
quantification |
3 |
|
random allocation |
3 |
|
randomized controlled trials as topic |
3 |
|
reagent kits, diagnostic |
3 |
|
referral and consultation - organization & administration |
3 |
|
reishi |
3 |
|
remdesivir |
3 |
|
retina |
3 |
|
retinal vessels - drug effects |
3 |
|
review |
3 |
|
ribavirin - pharmacology - therapeutic use |
3 |
|
rna interference |
3 |
|
rna, viral - analysis |
3 |
|
rna, viral - blood |
3 |
|
rna, viral - genetics |
3 |
|
sars-cov-2 |
3 |
|
serum albumin |
3 |
|
silver poisoning / intoxication |
3 |
|
sphincterotomy, endoscopic |
3 |
|
sphincterotomy, endoscopic - methods |
3 |
|
stents |
3 |
|
stents - adverse effects |
3 |
|
systematic review |
3 |
|
systemic interferon |
3 |
|
treatment cessation |
3 |
|
tumor response |
3 |
|
ultrasonography, doppler |
3 |
|
unresectable hepatocellular carcinoma |
3 |
|
upper endoscopy |
3 |
|
viral proteins - physiology |
3 |
|
viremia - epidemiology - virology |
3 |
|
virulence factors - physiology |
3 |
|
virus replication - drug effects |
3 |
|
2-aminopurine - adverse effects - analogs & derivatives - therapeutic use |
2 |
|
acute hepatic decompensation |
2 |
|
acute hepatitis |
2 |
|
adefovir dipivoxil |
2 |
|
adenine - adverse effects - analogs & derivatives - therapeutic use |
2 |
|
adenine - analogs & derivatives - pharmacokinetics - therapeutic use |
2 |
|
adenine - analogs & derivatives - pharmacology |
2 |
|
adenine - analogs & derivatives - pharmacology - therapeutic use |
2 |
|
adenine - analogs and derivatives - therapeutic use |
2 |
|
adjuvants, immunologic - pharmacology - therapeutic use |
2 |
|
administration, oral |
2 |
|
adrenal cortex hormones - adverse effects - therapeutic use |
2 |
|
albumins - analysis |
2 |
|
alkaline phosphatase - metabolism |
2 |
|
alpha-fetoprotein |
2 |
|
alt |
2 |
|
alt normalization |
2 |
|
amino acid sequence |
2 |
|
amino acid substitution |
2 |
|
ampulla of vater - surgery |
2 |
|
animals |
2 |
|
anti-bacterial agents - adverse effects - therapeutic use |
2 |
|
anti-bacterial agents - therapeutic use |
2 |
|
anti-inflammatory agents, non-steroidal - administration & dosage - adverse effects |
2 |
|
anti-ulcer agents - adverse effects - therapeutic use |
2 |
|
antibiotics |
2 |
|
antidepressive agents, tricyclic - adverse effects |
2 |
|
antigenemia |
2 |
|
antigens, cd4 - blood |
2 |
|
antigens, cd8 |
2 |
|
antigens, differentiation, t-lymphocyte - blood |
2 |
|
antineoplastic agents - administration and dosage |
2 |
|
antineoplastic agents - adverse effects |
2 |
|
antineoplastic combined chemotherapy protocols - adverse effects |
2 |
|
antithrombin iii - metabolism |
2 |
|
antithyroid agents |
2 |
|
antithyroid agents - administration & dosage - adverse effects |
2 |
|
antitrichomonal agents - therapeutic use |
2 |
|
antitubercular agents - adverse effects |
2 |
|
antitubercular agents - therapeutic use |
2 |
|
antiviral agents |
2 |
|
antiviral agents - administration & dosage - therapeutic use |
2 |
|
antiviral agents - chemistry - pharmacology - therapeutic use |
2 |
|
antiviral agents - chemistry - therapeutic use |
2 |
|
antiviral agents - pharmacokinetics - therapeutic use |
2 |
|
antivirals |
2 |
|
ascites - metabolism |
2 |
|
asia - epidemiology |
2 |
|
asia, southeastern |
2 |
|
aspirin - administration & dosage - adverse effects |
2 |
|
asthma |
2 |
|
autoantibodies - analysis |
2 |
|
autoantibodies - biosynthesis |
2 |
|
biliary pathology |
2 |
|
bleomycin - administration & dosage |
2 |
|
blood - immunology |
2 |
|
blood preservation |
2 |
|
breath tests |
2 |
|
campylobacter - isolation & purification |
2 |
|
campylobacter infections - complications - microbiology - pathology |
2 |
|
carbimazole |
2 |
|
carbimazole - administration & dosage - adverse effects |
2 |
|
carcinoma, hepatocellular - blood supply - mortality - therapy |
2 |
|
carcinoma, hepatocellular - complications - radiography |
2 |
|
carcinoma, hepatocellular - diagnosis - economics - pathology |
2 |
|
carcinoma, hepatocellular - diagnosis - epidemiology - surgery |
2 |
|
carcinoma, hepatocellular - diagnosis - physiopathology - therapy - ultrasonography |
2 |
|
carcinoma, hepatocellular - etiology - genetics |
2 |
|
carcinoma, hepatocellular - genetics - physiopathology |
2 |
|
carcinoma, hepatocellular - metabolism |
2 |
|
carcinoma, hepatocellular - mortality |
2 |
|
carcinoma, hepatocellular - mortality - prevention & control - therapy - virology |
2 |
|
carcinoma, hepatocellular - prevention and control |
2 |
|
carcinoma, hepatocellular - prevention and control - virology |
2 |
|
carcinoma, hepatocellular - secondary - surgery - ultrasonography |
2 |
|
carcinoma, squamous cell - epidemiology - pathology |
2 |
|
cardiac metastasis |
2 |
|
catheterization |
2 |
|
catheterization, peripheral |
2 |
|
cell cycle |
2 |
|
cell transformation, neoplastic |
2 |
|
chi-square distribution |
2 |
|
chinese |
2 |
|
cholangitis - diagnosis - physiopathology - surgery |
2 |
|
cholangitis - prevention & control |
2 |
|
cholangitis - surgery |
2 |
|
cholecystectomy |
2 |
|
cholelithiasis - complications |
2 |
|
cholestasis |
2 |
|
chronic active hepatitis |
2 |
|
chronic hepatitis b infection |
2 |
|
chronic hepatitis b, ymdd hbv variant |
2 |
|
chronic obstructive pulmonary disease |
2 |
|
cimetidine - therapeutic use |
2 |
|
cisplatin - administration & dosage - adverse effects |
2 |
|
clarithromycin - adverse effects - therapeutic use |
2 |
|
clinical trials, phase i as topic |
2 |
|
clinical trials, phase ii as topic |
2 |
|
colo-vesical fistula |
2 |
|
communicable diseases |
2 |
|
contrast media |
2 |
|
contrast media - administration & dosage - therapeutic use |
2 |
|
core promoter |
2 |
|
cost-benefit analysis |
2 |
|
cost-effectiveness |
2 |
|
costs and cost analysis |
2 |
|
crohn disease - diagnosis |
2 |
|
crohn's disease |
2 |
|
cross-linking reagents |
2 |
|
cyclophosphamide - administration & dosage |
2 |
|
cyclophosphamide - administration & dosage - adverse effects |
2 |
|
des-gamma-carboxyprothrombin |
2 |
|
dexamethasone - administration & dosage |
2 |
|
diabetes complications |
2 |
|
diabetes mellitus |
2 |
|
diagnosis, differential |
2 |
|
direct-acting antivirals |
2 |
|
dna probes |
2 |
|
dna, viral - analysis - drug effects |
2 |
|
dna, viral - analysis - metabolism |
2 |
|
doxorubicin - administration & dosage |
2 |
|
drug therapy, combination - therapeutic use |
2 |
|
drug-induced liver injury - etiology |
2 |
|
drug-induced liver injury - etiology - pathology |
2 |
|
duodenal ulcer |
2 |
|
duodenal ulcer - complications - pathology |
2 |
|
duodenal ulcer - drug therapy - microbiology - pathology |
2 |
|
duodenal ulcer - drug therapy - microbiology - prevention & control |
2 |
|
echocardiography, transesophageal |
2 |
|
embolization, therapeutic |
2 |
|
emulsions |
2 |
|
endoscopy, digestive system |
2 |
|
enhancer elements, genetic |
2 |
|
enhancer ii |
2 |
|
eradication |
2 |
|
erythropoietin |
2 |
|
european continental ancestry group |
2 |
|
evaluation studies as topic |
2 |
|
evolution, molecular |
2 |
|
extravasation of diagnostic and therapeutic materials - etiology - radiography |
2 |
|
factors affecting healing |
2 |
|
famciclovir |
2 |
|
fetoprotein screening |
2 |
|
fg-3019 |
2 |
|
fibrosis - etiology - prevention & control |
2 |
|
fibrosis - pathology |
2 |
|
forecasting |
2 |
|
gamma-glutamyltransferase - metabolism |
2 |
|
gastritis - drug therapy - etiology - microbiology - pathology |
2 |
|
gelatin sponge, absorbable - administration & dosage - adverse effects |
2 |
|
gene expression regulation, neoplastic |
2 |
|
genes, fos - genetics |
2 |
|
genes, jun - genetics |
2 |
|
genes, myc - genetics |
2 |
|
genetic variation |
2 |
|
genome, viral |
2 |
|
genome, viral - genetics |
2 |
|
genotypes |
2 |
|
gingival neoplasms - epidemiology - pathology |
2 |
|
globe trial |
2 |
|
glypican-3 |
2 |
|
glypicans |
2 |
|
gram-negative bacterial infections - microbiology - mortality - pathology - therapy |
2 |
|
gram-positive bacterial infections - microbiology - mortality - pathology - therapy |
2 |
|
guanine - administration & dosage - adverse effects - analogs & derivatives - pharmacokinetics - therapeutic use |
2 |
|
guanine - adverse effects - analogs & derivatives - therapeutic use |
2 |
|
guanine - analogs and derivatives - pharmacology - therapeutic use |
2 |
|
guidelines |
2 |
|
haemodialysis |
2 |
|
half-life |
2 |
|
hbeag loss |
2 |
|
hbeag negative |
2 |
|
hbeag positive |
2 |
|
hbeag serconversion |
2 |
|
hbv dna levels |
2 |
|
hbv genotype ba, bj, c |
2 |
|
hcv genotype |
2 |
|
hcv rna |
2 |
|
heart neoplasms - secondary - ultrasonography |
2 |
|
heart rate |
2 |
|
helicobacter infections - blood - diagnosis - microbiology |
2 |
|
helicobacter infections - complications - drug therapy |
2 |
|
helicobacter infections - drug therapy - ethnology |
2 |
|
helicobacter infections - drug therapy - microbiology |
2 |
|
helicobacter pylori - drug effects |
2 |
|
helicobacter pylori - drug effects - isolation & purification |
2 |
|
helipsav |
2 |
|
hemorrhage - etiology - radiography - therapy |
2 |
|
hepacivirus - classification - genetics - isolation & purification |
2 |
|
hepacivirus - classification - isolation & purification |
2 |
|
hepacivirus - drug effects |
2 |
|
hepacivirus - genetics - isolation & purification |
2 |
|
hepatic arteries, chemotherapeutic infusion, 952.1266 |
2 |
|
hepatic arteries, therapeutic blockade, 952.1264 |
2 |
|
hepatic artery - radiography |
2 |
|
hepatitis |
2 |
|
hepatitis - complications |
2 |
|
hepatitis antibodies - blood |
2 |
|
hepatitis b - blood - drug therapy - prevention & control |
2 |
|
hepatitis b - chemically induced - immunology - virology |
2 |
|
hepatitis b - chemically induced - microbiology - mortality |
2 |
|
hepatitis b - complications - epidemiology |
2 |
|
hepatitis b - complications - mortality - prevention & control |
2 |
|
hepatitis b - diagnosis |
2 |
|
hepatitis b - drug therapy |
2 |
|
hepatitis b - drug therapy - epidemiology - virology |
2 |
|
hepatitis b - drug therapy - immunology |
2 |
|
hepatitis b - enzymology - ethnology - immunology - physiopathology |
2 |
|
hepatitis b - prevention & control - therapy - transmission |
2 |
|
hepatitis b antibodies - analysis - biosynthesis |
2 |
|
hepatitis b antibodies - immunology |
2 |
|
hepatitis b e antigens - analysis - immunology |
2 |
|
hepatitis b e antigens - blood - immunology |
2 |
|
hepatitis b e antigens - immunology |
2 |
|
hepatitis b e antigens - isolation & purification |
2 |
|
hepatitis b reactivation |
2 |
|
hepatitis b surface antigens - analysis |
2 |
|
hepatitis b surface antigens - isolation & purification |
2 |
|
hepatitis b vaccines - administration & dosage - therapeutic use |
2 |
|
hepatitis b vaccines - therapeutic use |
2 |
|
hepatitis b virus - classification - drug effects - genetics |
2 |
|
hepatitis b virus - drug effects - genetics - physiology |
2 |
|
hepatitis b virus - drug effects - isolation & purification - physiology |
2 |
|
hepatitis b virus - drug effects - physiology |
2 |
|
hepatitis b virus - genetics - immunology - pathogenicity |
2 |
|
hepatitis b virus - genetics - pathogenicity |
2 |
|
hepatitis b virus - metabolism |
2 |
|
hepatitis b virus. |
2 |
|
hepatitis b, chronic - blood - drug therapy - enzymology - virology |
2 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy |
2 |
|
hepatitis b, chronic - complications - immunology - virology |
2 |
|
hepatitis b, chronic - drug therapy - economics |
2 |
|
hepatitis b, chronic - drug therapy - epidemiology - immunology - virology |
2 |
|
hepatitis b, chronic - drug therapy - epidemiology - virology |
2 |
|
hepatitis b, chronic - drug therapy - immunology |
2 |
|
hepatitis b, chronic - genetics - virology |
2 |
|
hepatitis b, chronic - immunology - pathology - virology |
2 |
|
hepatitis c - complications - epidemiology - virology |
2 |
|
hepatitis c - complications - mortality - prevention & control |
2 |
|
hepatitis c - drug therapy - pathology - virology |
2 |
|
hepatitis c - enzymology - immunology - surgery |
2 |
|
hepatitis c - etiology - metabolism - pathology |
2 |
|
hepatitis c virus (hcv) |
2 |
|
hepatitis d - complications - epidemiology |
2 |
|
hepatitis, chronic - etiology - metabolism - pathology |
2 |
|
hepatocarcinogenesis |
2 |
|
hepatocellular carcinoma (hcc) |
2 |
|
hepatocellular carcinoma, subclinical |
2 |
|
hepatotoxicity |
2 |
|
hiv infections - drug therapy - epidemiology |
2 |
|
hla-dr antigens - blood |
2 |
|
hypothyroidism - etiology |
2 |
|
immunoelectrophoresis, two-dimensional |
2 |
|
immunoglobulin g - analysis |
2 |
|
immunosuppressive agents - administration & dosage - adverse effects |
2 |
|
india |
2 |
|
infusions, intra-arterial |
2 |
|
interferon α |
2 |
|
interferon-alpha - administration & dosage - therapeutic use |
2 |
|
interferon-alpha - adverse effects - pharmacology - therapeutic use |
2 |
|
interferon-alpha - pharmacology - therapeutic use |
2 |
|
interferon-gamma - adverse effects - therapeutic use |
2 |
|
interferon-λ |
2 |
|
interleukin-2 - adverse effects - therapeutic use |
2 |
|
intestinal fistula - diagnosis - drug therapy - microbiology |
2 |
|
intestinal tuberculosis |
2 |
|
iodine radioisotopes - diagnostic use |
2 |
|
iodized oil - administration & dosage - adverse effects |
2 |
|
iodized oil - administration & dosage - therapeutic use |
2 |
|
iodized oil - administration and dosage |
2 |
|
jaundice, obstructive - chemically induced |
2 |
|
kidney diseases - chemically induced |
2 |
|
kidney transplantation - immunology |
2 |
|
leucovorin - administration & dosage |
2 |
|
liver - diseases. |
2 |
|
liver - drug effects |
2 |
|
liver - drug effects - pathology |
2 |
|
liver - enzymology - pathology |
2 |
|
liver - microbiology |
2 |
|
liver - pathology - physiopathology |
2 |
|
liver - physiopathology |
2 |
|
liver abscess - microbiology - mortality - pathology - therapy |
2 |
|
liver cancer |
2 |
|
liver cirrhosis - chemically induced - physiopathology |
2 |
|
liver cirrhosis - metabolism |
2 |
|
liver diseases - enzymology - pathology |
2 |
|
liver diseases - immunology |
2 |
|
liver diseases - pathology - physiopathology |
2 |
|
liver neoplasms - blood supply - mortality - therapy |
2 |
|
liver neoplasms - complications - radiography |
2 |
|
liver neoplasms - diagnosis |
2 |
|
liver neoplasms - diagnosis - economics - pathology |
2 |
|
liver neoplasms - diagnosis - epidemiology - surgery |
2 |
|
liver neoplasms - diagnosis - physiopathology - therapy - ultrasonography |
2 |
|
liver neoplasms - etiology - genetics |
2 |
|
liver neoplasms - genetics - physiopathology |
2 |
|
liver neoplasms - metabolism |
2 |
|
liver neoplasms - mortality |
2 |
|
liver neoplasms - mortality - prevention & control - therapy - virology |
2 |
|
liver neoplasms - pathology - surgery |
2 |
|
liver neoplasms - prevention and control |
2 |
|
liver neoplasms - prevention and control - virology |
2 |
|
liver neoplasms, therapy, 761.321, 952.1266 |
2 |
|
long-term care |
2 |
|
lymphoma |
2 |
|
lymphoma - complications - immunology - therapy |
2 |
|
lymphoma, non-hodgkin - drug therapy |
2 |
|
malignancy |
2 |
|
mass screening |
2 |
|
mass screening - economics |
2 |
|
medicine |
2 |
|
membrane proteins - blood |
2 |
|
mental health |
2 |
|
methotrexate - administration & dosage |
2 |
|
metronidazole - administration & dosage |
2 |
|
metronidazole - adverse effects - therapeutic use |
2 |
|
metronidazole - therapeutic use |
2 |
|
metronidazole susceptibility |
2 |
|
mianserin - adverse effects - analogs & derivatives |
2 |
|
mice |
2 |
|
mirtazapine |
2 |
|
molecular sequence data |
2 |
|
molecular structure |
2 |
|
mouth neoplasms - epidemiology - pathology |
2 |
|
mutation, missense |
2 |
|
neoplasm proteins - blood |
2 |
|
nucleic acid hybridization |
2 |
|
nucleic acid hybridization - methods |
2 |
|
nucleoside analogs |
2 |
|
nucleosides - chemistry - pharmacology - therapeutic use |
2 |
|
nucleotides - administration & dosage - adverse effects - chemistry - pharmacokinetics |
2 |
|
omeprazole - adverse effects - therapeutic use |
2 |
|
palatal neoplasms - epidemiology - pathology |
2 |
|
palliative care |
2 |
|
pathology |
2 |
|
phenotype |
2 |
|
phosphonic acids - administration & dosage - adverse effects - pharmacokinetics - therapeutic use |
2 |
|
phosphonic acids - adverse effects - therapeutic use |
2 |
|
phosphonic acids - pharmacokinetics - therapeutic use |
2 |
|
phosphonic acids - pharmacology |
2 |
|
physical functioning |
2 |
|
plant lectins |
2 |
|
plasma |
2 |
|
point mutation |
2 |
|
policy |
2 |
|
polymorphism, restriction fragment length |
2 |
|
postoperative hemorrhage - chemically induced - prevention & control |
2 |
|
practice guidelines as topic - standards |
2 |
|
precore genome |
2 |
|
prednisone - administration & dosage |
2 |
|
prodrugs - administration & dosage - adverse effects - metabolism - pharmacokinetics |
2 |
|
proliferation |
2 |
|
prolonged jaundice |
2 |
|
propylthiouracil |
2 |
|
propylthiouracil - administration & dosage - adverse effects |
2 |
|
protein precursors - blood |
2 |
|
prothrombin |
2 |
|
public health |
2 |
|
pyloric antrum - microbiology - pathology |
2 |
|
pyogenic liver abscess |
2 |
|
pyrimidinones - chemistry - pharmacology - therapeutic use |
2 |
|
recombination, genetic |
2 |
|
rep 9ac |
2 |
|
research design |
2 |
|
resistant mutation |
2 |
|
reverse transcriptase inhibitors - pharmacology - therapeutic use |
2 |
|
ribavirin - administration & dosage - therapeutic use |
2 |
|
risk |
2 |
|
risk factors for mortality |
2 |
|
risk prediction |
2 |
|
rupture, spontaneous |
2 |
|
screening |
2 |
|
sequence analysis, dna |
2 |
|
sequence homology, amino acid |
2 |
|
seroconversion |
2 |
|
serologic tests - methods - standards |
2 |
|
serological marker |
2 |
|
single nucleotides polymorphisms |
2 |
|
single-blind method |
2 |
|
sjogren's syndrome - drug therapy - pathology |
2 |
|
societies, medical |
2 |
|
sofosbuvir |
2 |
|
space-time clustering |
2 |
|
species specificity |
2 |
|
subgenotype c |
2 |
|
subgenotypes |
2 |
|
substance withdrawal syndrome |
2 |
|
substance-related disorders |
2 |
|
sucralfate - adverse effects - therapeutic use |
2 |
|
sucralfate - therapeutic use |
2 |
|
surgical procedures, elective |
2 |
|
systemic corticosteroid |
2 |
|
t-cell exhaustion |
2 |
|
t-lymphocyte subsets - drug effects |
2 |
|
thyroid diseases - etiology - physiopathology |
2 |
|
thyroid function tests |
2 |
|
thyroid gland - drug effects - physiology |
2 |
|
thyroid gland - immunology - physiopathology |
2 |
|
thyroiditis, autoimmune - chemically induced |
2 |
|
thyrotoxicosis - drug therapy |
2 |
|
tongue neoplasms - epidemiology - pathology |
2 |
|
transcatheter intraarterial lipiodol chemoembolization (tace) |
2 |
|
transesophageal echocardiography |
2 |
|
transplantation, homologous - adverse effects |
2 |
|
tuberculosis, gastrointestinal - diagnosis - drug therapy |
2 |
|
tyrosine-methionine-aspartate-aspartate (ymdd) mutations |
2 |
|
ultrasonography |
2 |
|
ultrasonography - economics |
2 |
|
united states - epidemiology |
2 |
|
urea - metabolism |
2 |
|
vaccines, dna - administration & dosage - therapeutic use |
2 |
|
vascular neoplasms - secondary - ultrasonography |
2 |
|
vincristine - administration & dosage |
2 |
|
viral hepatitis vaccines - immunology |
2 |
|
viral resistance |
2 |
|
viremia |
2 |
|
virus activation - drug effects |
2 |
|
vitality |
2 |
|
yeasts |
2 |
|
ymdd mutants |
2 |
|
α-fetoprotein |
2 |
|
3'-end labelling |
1 |
|
acid |
1 |
|
adenocarcinoma - pathology - ultrastructure |
1 |
|
adenoma, bile duct - diagnosis |
1 |
|
adverse events |
1 |
|
africa |
1 |
|
alanine transaminase |
1 |
|
albumin |
1 |
|
alcohol drinking |
1 |
|
aluminum - therapeutic use |
1 |
|
aluminum hydroxide - administration & dosage - adverse effects - therapeutic use |
1 |
|
amino acid motifs |
1 |
|
amino acid sequence - genetics |
1 |
|
analgesics - therapeutic use |
1 |
|
angiography |
1 |
|
anorexia - diagnosis |
1 |
|
antacids - administration & dosage - adverse effects - therapeutic use |
1 |
|
antacids - therapeutic use |
1 |
|
anti-inflammatory agents - therapeutic use |
1 |
|
antibodies - immunology |
1 |
|
antibodies, monoclonal - diagnostic use |
1 |
|
antigenic sites |
1 |
|
antigens, differentiation - analysis |
1 |
|
antiviral agents - administration & dosage - adverse effects - pharmacokinetics - pharmacology - therapeutic use |
1 |
|
antiviral agents - administration & dosage - adverse effects - therapeutic use |
1 |
|
antiviral agents - adverse effects |
1 |
|
antiviral agents - adverse effects - pharmacology - therapeutic use |
1 |
|
antiviral agents - pharmacology |
1 |
|
anti‐hav prevalence |
1 |
|
anti‐hbs titre |
1 |
|
antral gastritis |
1 |
|
area under curve |
1 |
|
asia, southeastern - epidemiology |
1 |
|
asians |
1 |
|
assay |
1 |
|
audit |
1 |
|
autoradiography |
1 |
|
b-lymphocytes - immunology |
1 |
|
base composition |
1 |
|
base sequence - genetics |
1 |
|
bcl-2 |
1 |
|
bedtime cimetidine |
1 |
|
beta 2-microglobulin - analysis |
1 |
|
bile acids |
1 |
|
bile ducts - immunology |
1 |
|
bilirubin |
1 |
|
biopsy, fine-needle |
1 |
|
blood |
1 |
|
blood donor |
1 |
|
blotting, southern |
1 |
|
bone diseases - etiology - radiography |
1 |
|
campylobacter |
1 |
|
capsules |
1 |
|
carcinoma, hepatocellular - blood - drug therapy |
1 |
|
carcinoma, hepatocellular - classification - immunology - mortality - pathology |
1 |
|
carcinoma, hepatocellular - diagnosis |
1 |
|
carcinoma, hepatocellular - diagnosis - mortality |
1 |
|
carcinoma, hepatocellular - drug therapy |
1 |
|
carcinoma, hepatocellular - enzymology |
1 |
|
carcinoma, hepatocellular - epidemiology - etiology |
1 |
|
carcinoma, hepatocellular - epidemiology - genetics |
1 |
|
carcinoma, hepatocellular - epidemiology - mortality - pathology |
1 |
|
carcinoma, hepatocellular - etiology - microbiology |
1 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology |
1 |
|
carcinoma, hepatocellular - mortality - pathology |
1 |
|
carcinoma, hepatocellular - mortality - radiography - therapy |
1 |
|
carcinoma, hepatocellular - pathology |
1 |
|
carcinoma, hepatocellular - pathology - ultrastructure |
1 |
|
carcinoma, renal cell - complications |
1 |
|
carrier state - diagnosis - epidemiology - ethnology - genetics |
1 |
|
carrier state - epidemiology |
1 |
|
carrier state - epidemiology - transmission |
1 |
|
carrier state - immunology |
1 |
|
carrier state - immunology - microbiology |
1 |
|
carrier state - microbiology - therapy |
1 |
|
carrier state - therapy |
1 |
|
celiac disease - diagnosis - therapy |
1 |
|
cell death |
1 |
|
cell division |
1 |
|
cell movement |
1 |
|
cell nucleus - virology |
1 |
|
cell turnover |
1 |
|
ceruloplasmin - analysis |
1 |
|
chemotheraphy |
1 |
|
china - epidemiology |
1 |
|
chinese heritage |
1 |
|
chinese patients |
1 |
|
cholangitis - enzymology |
1 |
|
cholestasis, extrahepatic - diagnosis |
1 |
|
cholestasis, intrahepatic - diagnosis |
1 |
|
chronic active hepatitis (cah) |
1 |
|
chronic hepatitis b virus infection |
1 |
|
chronic liver diseases |
1 |
|
cimetidine - administration & dosage |
1 |
|
cimetidine - administration & dosage - adverse effects - therapeutic use |
1 |
|
cimetidine - administration & dosage - therapeutic use |
1 |
|
cimetidine - adverse effects - therapeutic use |
1 |
|
cimetidine - pharmacology |
1 |
|
cirrhosis clinical picture |
1 |
|
computer algorithms |
1 |
|
consensus sequence |
1 |
|
conserved sequence - genetics - immunology |
1 |
|
coronavirus - genetics - isolation & purification |
1 |
|
creatinine - analysis |
1 |
|
cryoglobulinemia |
1 |
|
cytoplasm - chemistry |
1 |
|
cytoplasm - virology |
1 |
|
data collection |
1 |
|
death |
1 |
|
delayed-action preparations |
1 |
|
deoxycytosine nucleotides - metabolism |
1 |
|
depression, chemical |
1 |
|
dinoprostone - administration & dosage - adverse effects |
1 |
|
diseases in twins - genetics |
1 |
|
dna fragmentation |
1 |
|
dna polymerase |
1 |
|
dna probe |
1 |
|
dna probes - genetics |
1 |
|
dna, circular - analysis - genetics |
1 |
|
dna, neoplasm - analysis |
1 |
|
dna, superhelical - analysis |
1 |
|
dna, viral - analysis - blood |
1 |
|
dna, viral - antagonists & inhibitors - blood |
1 |
|
dna, viral - chemistry |
1 |
|
dna,-viral-chemistry |
1 |
|
dna-directed dna polymerase - analysis |
1 |
|
dna-directed dna polymerase - antagonists & inhibitors - blood |
1 |
|
dna-directed dna polymerase - blood |
1 |
|
doxorubicin - adverse effects - therapeutic use |
1 |
|
doxorubicin - therapeutic use |
1 |
|
drug administration schedule |
1 |
|
drug combinations |
1 |
|
drug evaluation |
1 |
|
drug interactions |
1 |
|
drug tolerance |
1 |
|
ductal enzymes |
1 |
|
duodenal ulcer - blood - complications - physiopathology |
1 |
|
duodenal ulcer - complications |
1 |
|
duodenal ulcer - complications - drug therapy - microbiology |
1 |
|
duodenal ulcer - drug therapy |
1 |
|
duodenal ulcer - drug therapy - epidemiology - pathology |
1 |
|
duodenal ulcer - drug therapy - physiopathology |
1 |
|
duodenal ulcer healing |
1 |
|
duodenitis |
1 |
|
duodenitis - complications - microbiology |
1 |
|
duodenoscopy |
1 |
|
duodenum - microbiology |
1 |
|
eating |
1 |
|
egypt - epidemiology |
1 |
|
electrocoagulation |
1 |
|
electrophoresis, agar gel |
1 |
|
endoscopy |
1 |
|
enterocolitis, pseudomembranous - etiology |
1 |
|
epitopes - genetics |
1 |
|
ethnic groups |
1 |
|
europe |
1 |
|
evolution |
1 |
|
expenditure on colloids |
1 |
|
family |
1 |
|
far east - epidemiology |
1 |
|
fasting |
1 |
|
fibrosis progression |
1 |
|
follicle stimulating hormone - blood |
1 |
|
food |
1 |
|
foscarnet |
1 |
|
fulminant liver failure |
1 |
|
gallbladder - pathology |
1 |
|
gallbladder diseases - pathology |
1 |
|
gastric acid - secretion |
1 |
|
gastric fundus - microbiology |
1 |
|
gastric juice - secretion |
1 |
|
gastrins - blood |
1 |
|
gastrins - secretion |
1 |
|
gastritis |
1 |
|
gastritis - complications - microbiology |
1 |
|
gastritis - drug therapy - etiology - microbiology |
1 |
|
gastroscopy |
1 |
|
gene rearrangement, beta-chain t-cell antigen receptor |
1 |
|
genes, viral |
1 |
|
genes, viral - genetics |
1 |
|
genetic techniques |
1 |
|
genetic variation - genetics |
1 |
|
genetic variation - physiology |
1 |
|
genome |
1 |
|
genotype 4 |
1 |
|
genotype 5 |
1 |
|
glomerular diseases |
1 |
|
glomerulonephritis |
1 |
|
gonadal steroid hormones - blood |
1 |
|
granuloma, plasma cell - pathology - radiography - surgery |
1 |
|
green cross hepatitis b vaccine |
1 |
|
guanidines - adverse effects |
1 |
|
guanidines - pharmacology |
1 |
|
guanine - administration & dosage - adverse effects - analogs & derivatives - therapeutic use |
1 |
|
guanine - analogs & derivatives - pharmacology - therapeutic use |
1 |
|
guideline |
1 |
|
hapatitis, chronic active |
1 |
|
hbeag-negative |
1 |
|
hbv antigens |
1 |
|
health personnel |
1 |
|
heart defects, congenital - complications |
1 |
|
helicobacter infections - drug therapy |
1 |
|
hemodynamics - drug effects |
1 |
|
hepacivirus - classification - genetics - immunology - isolation & purification |
1 |
|
hepatic encephalopathy - etiology |
1 |
|
hepatitis - complications - mortality |
1 |
|
hepatitis - drug therapy |
1 |
|
hepatitis a |
1 |
|
hepatitis a - blood - epidemiology |
1 |
|
hepatitis a vaccine |
1 |
|
hepatitis antibodies - analysis |
1 |
|
hepatitis b - blood |
1 |
|
hepatitis b - blood - epidemiology |
1 |
|
hepatitis b - blood - epidemiology - therapy |
1 |
|
hepatitis b - blood - ethnology - virology |
1 |
|
hepatitis b - blood - therapy |
1 |
|
hepatitis b - complications - epidemiology - mortality - transmission |
1 |
|
hepatitis b - complications - mortality - pathology |
1 |
|
hepatitis b - diagnosis - epidemiology - ethnology - genetics |
1 |
|
hepatitis b - drug therapy - epidemiology - pathology |
1 |
|
hepatitis b - enzymology |
1 |
|
hepatitis b - epidemiology |
1 |
|
hepatitis b - epidemiology - ethnology - physiopathology |
1 |
|
hepatitis b - epidemiology - genetics |
1 |
|
hepatitis b - epidemiology - immunology - prevention & control |
1 |
|
hepatitis b - epidemiology - prevention & control |
1 |
|
hepatitis b - epidemiology - transmission |
1 |
|
hepatitis b - epidemiology - virology |
1 |
|
hepatitis b - ethnology - genetics - transmission |
1 |
|
hepatitis b - ethnology - immunology - pathology |
1 |
|
hepatitis b - ethnology - pathology |
1 |
|
hepatitis b - ethnology - therapy |
1 |
|
hepatitis b - genetics - immunology - prevention & control |
1 |
|
hepatitis b - immunology |
1 |
|
hepatitis b - immunology - therapy |
1 |
|
hepatitis b - microbiology |
1 |
|
hepatitis b - microbiology - therapy |
1 |
|
hepatitis b - pathology - physiopathology |
1 |
|
hepatitis b - pathology - therapy |
1 |
|
hepatitis b - pathology - virology |
1 |
|
hepatitis b - therapy |
1 |
|
hepatitis b antigens - analysis |
1 |
|
hepatitis b core antigens |
1 |
|
hepatitis b core antigens - analysis |
1 |
|
hepatitis b e antigens |
1 |
|
hepatitis b e antigens - analysis - blood |
1 |
|
hepatitis b e antigens - analysis - genetics |
1 |
|
hepatitis b infection |
1 |
|
hepatitis b vaccine |
1 |
|
hepatitis b virus (hbv) |
1 |
|
hepatitis b virus - drug effects - genetics - immunology |
1 |
|
hepatitis b virus - enzymology |
1 |
|
hepatitis b virus - genetics - physiology |
1 |
|
hepatitis b virus - immunology |
1 |
|
hepatitis b virus - isolation & purification |
1 |
|
hepatitis b virus deoxyribonucleic acid |
1 |
|
hepatitis b, chronic - blood - drug therapy - pathology |
1 |
|
hepatitis b, chronic - blood - drug therapy - pathology - virology |
1 |
|
hepatitis b, chronic - diagnosis - drug therapy - immunology |
1 |
|
hepatitis b, chronic - drug therapy - genetics - pathology - virology |
1 |
|
hepatitis b, chronic - drug therapy - immunology - pathology - virology |
1 |
|
hepatitis b, chronic - drug therapy - pathology |
1 |
|
hepatitis b, chronic - drug therapy - physiopathology |
1 |
|
hepatitis b, chronic - therapy |
1 |
|
hepatitis c - blood - epidemiology - immunology - virology |
1 |
|
hepatitis c - complications |
1 |
|
hepatitis c - epidemiology - prevention & control |
1 |
|
hepatitis c viruses |
1 |
|
hepatitis c, chronic - blood - drug therapy - virology |
1 |
|
hepatitis c, chronic - therapy |
1 |
|
hepatitis d, chronic - complications |
1 |
|
hepatitis e - diagnosis - epidemiology - immunology |
1 |
|
hepatitis infection |
1 |
|
hepatitis, alcoholic - enzymology |
1 |
|
hepatitis, chronic - blood - epidemiology - therapy |
1 |
|
hepatitis, chronic - drug therapy |
1 |
|
hepatitis, chronic - drug therapy - pathology |
1 |
|
hepatitis, chronic - epidemiology |
1 |
|
hepatitis, chronic - ethnology - immunology - pathology |
1 |
|
hepatitis, chronic - pathology - virology |
1 |
|
hepatitis, chronic - therapy |
1 |
|
hepatitis, viral, human |
1 |
|
hepatitis, viral, human - drug therapy |
1 |
|
hepatitis, viral, human - drug therapy - pathology - virology |
1 |
|
hepatitis, viral, human - enzymology |
1 |
|
hepatitis, viral, human - history |
1 |
|
hepatitis-b-transmission |
1 |
|
hepatitis-b-virus-genetics |
1 |
|
hepatolenticular degeneration - blood - ethnology - genetics - pathology |
1 |
|
hepatolenticular degeneration - complications - genetics |
1 |
|
hepatoma |
1 |
|
hepatovirus - immunology |
1 |
|
herd immunity |
1 |
|
histamine h2 antagonists - pharmacology - therapeutic use |
1 |
|
history, 20th century |
1 |
|
hiv infections - complications |
1 |
|
hiv protease inhibitors - therapeutic use |
1 |
|
hormones - blood |
1 |
|
hypertrophy |
1 |
|
ifn-α |
1 |
|
ileal neoplasms - pathology - radiography - surgery |
1 |
|
imidazoles - adverse effects - therapeutic use |
1 |
|
immune globulin |
1 |
|
immune target |
1 |
|
immune tolerance |
1 |
|
in situ hybridization |
1 |
|
in situ nick-end labeling |
1 |
|
inappropriate adh syndrome - etiology |
1 |
|
infant, newborn |
1 |
|
infusions, intravenous |
1 |
|
injections, intramuscular |
1 |
|
inosine - analogs & derivatives |
1 |
|
inosine pranobex - therapeutic use |
1 |
|
institut pasteur hepatitis b vaccine |
1 |
|
interferon type i - administration & dosage - therapeutic use |
1 |
|
interferon type i - adverse effects - therapeutic use |
1 |
|
interferon type i - therapeutic use |
1 |
|
interferon-alpha - adverse effects - therapeutic use |
1 |
|
interferon-alpha - analysis |
1 |
|
interferon-alpha - immunology - therapeutic use |
1 |
|
interferon-gamma - analysis |
1 |
|
interferon-gamma - therapeutic use |
1 |
|
interferon-α therapy |
1 |
|
interferons - therapeutic use |
1 |
|
interferon‐gamma |
1 |
|
international cooperation |
1 |
|
intestines - blood supply |
1 |
|
intrahepatic cholestasis |
1 |
|
japan |
1 |
|
kdigo |
1 |
|
keratin-14 |
1 |
|
keratins - analysis |
1 |
|
kernel density analysis |
1 |
|
ki-67 antigen - metabolism |
1 |
|
kidney - drug effects |
1 |
|
kidney - drug effects - physiopathology |
1 |
|
kidney neoplasms - complications |
1 |
|
killer cells, natural - physiology |
1 |
|
lamivudine - administration & dosage - adverse effects |
1 |
|
lamivudine - administration & dosage - adverse effects - therapeutic use |
1 |
|
lamivudine - adverse effects |
1 |
|
lamivudine - adverse effects - pharmacology - therapeutic use |
1 |
|
large granular lymphocytosis |
1 |
|
leiomyosarcoma - pathology - radiography - surgery |
1 |
|
leukocyte count - drug effects |
1 |
|
life tables |
1 |
|
light coagulation |
1 |
|
likelihood functions |
1 |
|
linear models |
1 |
|
liver - chemistry |
1 |
|
liver - drug effects - pathology - virology |
1 |
|
liver - enzymology |
1 |
|
liver - immunology |
1 |
|
liver - immunology - pathology |
1 |
|
liver cirrhosis - diagnosis - epidemiology - etiology |
1 |
|
liver cirrhosis - drug therapy - etiology |
1 |
|
liver cirrhosis - drug therapy - pathology |
1 |
|
liver cirrhosis - etiology - pathology - virology |
1 |
|
liver cirrhosis - mortality - virology |
1 |
|
liver cirrhosis, alcoholic - epidemiology - etiology |
1 |
|
liver diseases - complications - virology |
1 |
|
liver diseases - ethnology - immunology - pathology |
1 |
|
liver diseases - history |
1 |
|
liver diseases - pathology - radiography - surgery |
1 |
|
liver diseases, alcoholic - complications - mortality - pathology |
1 |
|
liver diseases, alcoholic - diagnosis - enzymology |
1 |
|
liver diseases, alcoholic - pathology |
1 |
|
liver neoplasms - blood - drug therapy |
1 |
|
liver neoplasms - classification - immunology - mortality - pathology |
1 |
|
liver neoplasms - diagnosis - mortality |
1 |
|
liver neoplasms - diagnosis - pathology - radiography |
1 |
|
liver neoplasms - drug therapy |
1 |
|
liver neoplasms - enzymology |
1 |
|
liver neoplasms - epidemiology - etiology |
1 |
|
liver neoplasms - epidemiology - genetics |
1 |
|
liver neoplasms - epidemiology - mortality - pathology |
1 |
|
liver neoplasms - etiology - microbiology |
1 |
|
liver neoplasms - genetics - metabolism - pathology |
1 |
|
liver neoplasms - mortality - pathology |
1 |
|
liver neoplasms - mortality - radiography - therapy |
1 |
|
liver neoplasms - pathology |
1 |
|
liver neoplasms - pathology - ultrastructure |
1 |
|
liver neoplasms, experimental |
1 |
|
liver regeneration |
1 |
|
liver testing |
1 |
|
long covid-19 syndrome |
1 |
|
lopinavir |
1 |
|
lung diseases, obstructive - physiopathology |
1 |
|
luteinizing hormone - blood |
1 |
|
lymphocytosis - genetics - immunology - pathology |
1 |
|
lymphoma, large b-cell, diffuse - complications |
1 |
|
magnesium hydroxide - administration & dosage - adverse effects - therapeutic use |
1 |
|
maximum tolerated dose |
1 |
|
meal-time cimetidine |
1 |
|
methylprednisolone - therapeutic use |
1 |
|
microbial sensitivity tests |
1 |
|
microbiology |
1 |
|
microchemistry - methods |
1 |
|
microscopy, electron |
1 |
|
mitochondria, liver - pathology - ultrastructure |
1 |
|
mitosis |
1 |
|
models, genetic |
1 |
|
molecular adaptation |
1 |
|
molecular epidemiology |
1 |
|
molecular hybridization |
1 |
|
necrosis |
1 |
|
neoplasms, multiple primary - pathology - radiography - surgery |
1 |
|
neutralization tests |
1 |
|
neutrophils - pathology - physiology |
1 |
|
nosocomial transmission |
1 |
|
ns5a inhibitor |
1 |
|
ns5b inhibitor |
1 |
|
nucleic acid conformation |
1 |
|
nucleosides - administration & dosage - adverse effects |
1 |
|
nucleosides - administration & dosage - adverse effects - pharmacokinetics - pharmacology - therapeutic use |
1 |
|
nucleosides - adverse effects - pharmacology - therapeutic use |
1 |
|
nucleosides - adverse effects - therapeutic use |
1 |
|
oligodeoxyribonucleotides - diagnostic use |
1 |
|
oligonucleotide probe |
1 |
|
oligonucleotide probes |
1 |
|
omeprazole |
1 |
|
omeprazole - therapeutic use |
1 |
|
organophosphorus compounds - pharmacology |
1 |
|
osteochondritis - etiology |
1 |
|
osteochondritis dissecans - etiology - radiography |
1 |
|
p53 |
1 |
|
pangenotypic activity |
1 |
|
patient compliance |
1 |
|
patient dropouts |
1 |
|
peptic ulcer hemorrhage - diagnosis - pathology - surgery |
1 |
|
peripheral nervous system diseases - etiology |
1 |
|
pharmacology |
1 |
|
phase 1 |
1 |
|
phases of infection |
1 |
|
phosphonoacetic acid - analogs & derivatives - pharmacology |
1 |
|
phylogeny |
1 |
|
pirenzepine - administration & dosage - adverse effects - therapeutic use |
1 |
|
plasma protein fraction |
1 |
|
polymorphic t-cell receptor beta-chain gene rearrangement |
1 |
|
polymorphism,-genetic |
1 |
|
porphyrias - etiology |
1 |
|
post covid-19 syndrome |
1 |
|
prednisolone - adverse effects |
1 |
|
prednisolone - adverse effects - therapeutic use |
1 |
|
prednisone - therapeutic use |
1 |
|
primer design |
1 |
|
probability |
1 |
|
prolactin - blood |
1 |
|
proliferating cell nuclear antigen - metabolism |
1 |
|
proto-oncogene proteins c-bcl-2 - metabolism |
1 |
|
pyloric antrum |
1 |
|
pyloric antrum - microbiology |
1 |
|
pyrimidinones - administration & dosage - adverse effects |
1 |
|
pyrimidinones - administration & dosage - adverse effects - pharmacokinetics - pharmacology - therapeutic use |
1 |
|
pyrimidinones - adverse effects - pharmacology - therapeutic use |
1 |
|
pyrimidinones - adverse effects - therapeutic use |
1 |
|
pyrimidinones - therapeutic use |
1 |
|
radioautography |
1 |
|
radioimmunoassay |
1 |
|
ranitidine |
1 |
|
ranitidine - administration & dosage - adverse effects - therapeutic use |
1 |
|
ranitidine - adverse effects - therapeutic use |
1 |
|
ranitidine - therapeutic use |
1 |
|
reagent kits, diagnostic - statistics & numerical data |
1 |
|
recombinant proteins - administration & dosage - therapeutic use |
1 |
|
recombinant proteins - therapeutic use |
1 |
|
recovery |
1 |
|
recurrence. |
1 |
|
reference values |
1 |
|
regional blood flow - drug effects |
1 |
|
regression analysis |
1 |
|
rehabilitations |
1 |
|
remission, spontaneous |
1 |
|
renal cell carcinoma |
1 |
|
replication |
1 |
|
replicative intermediate |
1 |
|
response rate |
1 |
|
restriction mapping |
1 |
|
reverse transcriptase inhibitors - administration & dosage - adverse effects - therapeutic use |
1 |
|
ria |
1 |
|
risk assessment |
1 |
|
ritonavir - therapeutic use |
1 |
|
rna, viral - blood - genetics |
1 |
|
salmon |
1 |
|
scintillation counting |
1 |
|
secretory rate |
1 |
|
semen - cytology |
1 |
|
sequence alignment |
1 |
|
sequence homology, nucleic acid |
1 |
|
serologic tests - methods |
1 |
|
serotypes |
1 |
|
serum albumin - analysis |
1 |
|
serum alkaline phosphatase |
1 |
|
serum gamma-glutamyl transpeptidase |
1 |
|
serum globulins - analysis |
1 |
|
serum hepatitis b virus dna |
1 |
|
severe acute respiratory syndrome - complications - drug therapy - pathology |
1 |
|
sex characteristics |
1 |
|
skin diseases - etiology |
1 |
|
smoking |
1 |
|
southeast asia |
1 |
|
sperm count |
1 |
|
sperm motility - drug effects |
1 |
|
spermatozoa - drug effects |
1 |
|
staining and labeling |
1 |
|
stem cells - pathology |
1 |
|
stomach ulcer - blood - complications - physiopathology |
1 |
|
stomach ulcer - complications - drug therapy - pathology |
1 |
|
stress, psychological |
1 |
|
subcellular fractions - immunology |
1 |
|
sucralfate |
1 |
|
sucralfate - administration & dosage - adverse effects - therapeutic use |
1 |
|
sulpiride - administration & dosage - adverse effects - therapeutic use |
1 |
|
sulpiride - secretion |
1 |
|
synergism. |
1 |
|
t-lymphocytes - immunology |
1 |
|
t-lymphocytes - pathology - ultrastructure |
1 |
|
tablets |
1 |
|
taiwan |
1 |
|
terminology as topic |
1 |
|
testis - drug effects |
1 |
|
testosterone - blood |
1 |
|
tolerability |
1 |
|
trained immunity |
1 |
|
transaminases - blood |
1 |
|
transaminases - metabolism |
1 |
|
trimipramine - administration & dosage - adverse effects - therapeutic use |
1 |
|
tumor markers, biological - analysis |
1 |
|
tumor suppressor protein p53 - metabolism |
1 |
|
tunel |
1 |
|
vaccine |
1 |
|
vaccines, synthetic |
1 |
|
vaccines, synthetic - administration & dosage |
1 |
|
variability |
1 |
|
viral antigens |
1 |
|
viral core proteins - genetics - immunology |
1 |
|
viral hepatitis vaccines |
1 |
|
viral hepatitis vaccines - administration & dosage - adverse effects - immunology |
1 |
|
viral hepatitis vaccines - pharmacology |
1 |
|
viral nonstructural proteins - genetics |
1 |
|
viral nonstructural proteins - genetics - immunology |
1 |
|
viral suppressor |
1 |
|
viremia - microbiology |
1 |
|
virological cure |
1 |
|
volunteers |
1 |
|
wound healing |
1 |
|
wound healing - drug effects |
1 |
|
α-interferon treatment |
1 |
